pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,333 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1761Endpoints1375Fierce Biotech694BioSpace686BioPharma Dive519raps227onclive165fda recalls111
therapy area
allOncology12247Rare Disease3170Immunology2849Cardiology2694Hematology2136Pulmonology2133Vaccines
  • Anthropic appoints former Genentech scientist Nathan Frey to lead drug discovery after acquiring Coefficient Bio
    Anthropic, the AI company, recently bought biotech startup Coefficient Bio. Following the acquisition, the startup’s founder Nathan Frey, who previously worked at Genentech on machine‑learning proj…
    Endpoints · 10d agoNeutral↗ source
  • Former Be Bio chief Joanne Smith-Farrell appointed CEO of Orbis Medicines as Enanta CEO Jay Luly announces retirement
    Former Be Bio Pharmaceuticals CEO Joanne Smith-Farrell has joined Orbis Medicines as its new chief executive. Orbis, a startup backed by Eli Lilly and Novo Nordisk, focuses on developing oral macr…
    Endpoints · 10d agoNeutral↗ source
← prev
page 11 of 174
next →
fda medwatch107
globenewswire health73
fda press58
1775
Psychiatry & CNS1197
Ophthalmology1032
Endocrinology & Metabolism770
Pain768
Nephrology757
AI-Driven Biotech Startups May Soon Operate With Zero or One Employee, Says Endpoints News Live Discussion
Endpoints News hosted an AI-focused event in New York, after which executive editor Drew Armstrong announced a live discussion titled "Is biotech's future full of zero and one employee startups?" s…
Endpoints · 10d agoNeutral↗ source
  • Vitality Works recalls 365 Whole Foods Ashwagandha capsules over possible Salmonella contamination
    Vitality Works Inc., based in Albuquerque, NM, announced a recall of one lot of its 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha capsules, 120-count, due to potential Salmo…
    fda recalls · 10d agoRegulatoryNegative↗ source
  • Vir Biotechnology appoints David Liu as chief medical officer
    Vir Biotechnology announced the hiring of David Liu as its new chief medical officer. Liu joins the company after serving as chief medical officer at Nuvation Bio, where he held the same position.…
    STAT · 10d agoNeutral↗ source
  • Third Rock partner’s brain cancer diagnosis highlights personal impact of biotech drug development
    Jigar Raythatha, a partner at Third Rock Ventures, was diagnosed with a rare form of brain cancer in 2023 after a routine MRI. On the same day his diagnosis was confirmed, Servier announced posit…
    Fierce Biotech · 10d agoPositive↗ source
  • Once Upon a Farm recalls all Tractor Wheels toddler bars over choking risk
    Once Upon a Farm announced a recall of every lot and variety of its Tractor Wheels Organic Toddler Soft-Baked bars. The company said the snack can quickly turn into a dense, dry and sticky mass whe…
    fda recalls · 9d agoCRLNegative↗ source
  • 1834 measles letter highlights historic roots of today's anti-vaccine sentiment
    Jim Downs, a medical historian, examined a 1834 letter from Jane Butt in a London journal while at Yale's medical library, noting the date matches 192 years later. Butt described a measles outbrea…
    STAT · 10d agoNeutral↗ source
  • Eli Lilly beats Q3 revenue forecasts, lifts full-year outlook
    Eli Lilly reported third-quarter revenue of $24.4 billion, roughly $2 billion above analysts' expectations. The outperformance underscores the company's strong position, driven in part by its GLP-…
    Endpoints · 11d agoEarningsPositive↗ source
  • Voters demand action on soaring health-care costs, boosting support for Medicare for All
    Recent polls show Americans increasingly worried about the rising cost of health care, with many saying it is their top financial concern. Voter anger is directed at politicians, who are seen as f…
    STAT · 11d agoNegative↗ source
  • Bristol Myers Squibb emphasizes pipeline strength and later-stage partnership focus amid patent cliff concerns
    Bristol Myers Squibb used its latest earnings call to outline how it plans to address an upcoming patent cliff that threatens revenue from several key products. Executives said the company is rely…
    Endpoints · 11d agoEarningsPositive↗ source
  • BioMarin signs up to $475 million licensing deal for new Fabry disease enzyme therapy
    BioMarin announced a licensing agreement to acquire rights to a long‑acting enzyme replacement therapy candidate for Fabry disease, paying $70 million upfront and up to $405 million in development…
    Fierce Biotech · 11d agoDealPositive↗ source
  • Gilead places partial clinical hold on two KITE-753 CAR-T trials in diffuse large B-cell lymphoma
    Gilead announced on its third-quarter earnings call that it has placed a partial clinical hold on two CAR-T trials for KITE-753 targeting diffuse large B-cell lymphoma (DLBCL). The hold affects th…
    Fierce Biotech · 11d agoRegulatoryNegative↗ source
  • Merck R&D chief says company has outpaced rivals with its sac-TMT cancer platform
    Dean Li, the head of Merck Research Laboratories, said the company believes its sac-TMT cancer program gives it a competitive edge over other firms developing next-generation oncology therapies. T…
    Endpoints · 11d agoPositive↗ source
  • Federal rule forces PBMs to disclose fees and rebates to employers
    The Trump administration finalized a regulation that will require pharmacy benefit managers (PBMs) to reveal the various fees and compensation they receive from drugmakers, consultants and other pa…
    STAT · 11d agoRegulatoryPositive↗ source
  • UK secures £500m biopharma investment as Vertex commits over £300m to new Oxford R&D hub, while Teva plans New Jersey plant closure
    The UK government’s autumn budget has attracted about £500 million in new biopharma commitments, signalling strong support for the sector. Vertex Pharmaceuticals disclosed that it will put more th…
    Endpoints · 11d agoDealNeutral↗ source
  • Ono Pharma’s endocannabinoid drug ONO-1110 fails five Phase 2 trials, prompting broader concerns
    Ono Pharma reported that its experimental endocannabinoid modulator ONO-1110 did not achieve the primary efficacy endpoint in five separate Phase 2 clinical trials. The failures span multiple indi…
    Endpoints · 11d agoNegative readoutNegative↗ source
  • Genmab shares climb after head-and-neck cancer data as Iovance and Coherus stocks fall
    Genmab's shares moved higher after the company released data from a head‑and‑neck cancer trial, which investors interpreted as a positive signal for the drug's potential. In contrast, Iovance and…
    Endpoints · 11d agoPositive readoutNeutral↗ source
  • Big tech and startups are building personal AI agents to analyze patients’ medical records
    In a recent column the author notes that personal artificial-intelligence agents are poised to enter the healthcare arena. Large technology firms and emerging startups are creating platforms that…
    Endpoints · 11d agoNeutral↗ source
  • Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decision
    Vertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…
    STAT · 11d agoRegulatoryNeutral↗ source
  • Anthropic outlines biopharma strategy ahead of potential record-size IPO
    Anthropic, the AI startup that recently filed paperwork for what could become the largest initial public offering in business history, used its AI Day event to detail its biopharma ambitions. The…
    Endpoints · 11d agoNeutral↗ source
  • Genetic Testing Helps Refine Kidney Disease Trial Design, Says Natera Expert
    In a sponsored episode of The Top Line, Dr. Ronen Schneider, Natera's medical director of renal genetics, explains how genotype‑defined kidney disease data can improve clinical trial design. He not…
    Fierce Biotech · 11d agoPositive↗ source
  • Eli Lilly halts phase 2 Alzheimer's trial of mevidalen after missing internal targets
    Eli Lilly announced it is removing mevidalen from its pipeline, ending a phase 2 trial in symptomatic Alzheimer's disease. The decision was disclosed during the company's third-quarter earnings up…
    Fierce Biotech · 11d agoNegative readoutNegative↗ source
  • Setara Biosciences raises $90M Series A to advance neuroscience pipeline after Jazz's $820M Actio acquisition
    Jazz Pharmaceuticals completed an $820 million purchase of Actio Biosciences in September, creating a new spinout called Setara Biosciences to house the remaining drug programs. Setara has secured…
    Fierce Biotech · 11d agoDealPositive↗ source
  • Delays in reaching clinical proof-of-concept can dramatically increase biotech cash burn
    The article explains how the timing of achieving clinical proof‑of‑concept (POC) directly affects a biotech company's cash consumption. While a study’s cost is important, the ongoing expenses of st…
    Fierce Biotech · 11d agoNegative↗ source